Aprea Therapeutics (APRE) Projected to Post Quarterly Earnings on Tuesday

Aprea Therapeutics (NASDAQ:APRE) is projected to post its Q4 2025 results before the market opens on Tuesday, March 24th. Analysts expect Aprea Therapeutics to post earnings of ($0.38) per share for the quarter. Interested persons may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Friday, March 27, 2026 at 9:30 AM ET.

Aprea Therapeutics (NASDAQ:APRE) last released its quarterly earnings results on Monday, March 16th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.06. The firm had revenue of $0.00 million for the quarter. Aprea Therapeutics had a negative return on equity of 96.33% and a negative net margin of 4,405.59%. On average, analysts expect Aprea Therapeutics to post $-3 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Aprea Therapeutics Stock Down 0.2%

NASDAQ APRE opened at $0.76 on Friday. The stock has a market capitalization of $5.33 million, a P/E ratio of -0.38 and a beta of 1.42. Aprea Therapeutics has a 52-week low of $0.55 and a 52-week high of $2.44. The firm has a 50-day moving average price of $0.78 and a 200 day moving average price of $1.09.

Institutional Trading of Aprea Therapeutics

A hedge fund recently bought a new stake in Aprea Therapeutics stock. Jane Street Group LLC bought a new position in shares of Aprea Therapeutics, Inc. (NASDAQ:APRE) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 46,621 shares of the company’s stock, valued at approximately $40,000. Jane Street Group LLC owned 0.67% of Aprea Therapeutics as of its most recent filing with the Securities and Exchange Commission. 34.19% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts recently commented on the company. Wedbush dropped their target price on Aprea Therapeutics from $11.00 to $7.00 and set an “outperform” rating on the stock in a report on Tuesday, February 10th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Aprea Therapeutics in a research report on Wednesday, January 21st. HC Wainwright restated a “buy” rating and issued a $4.00 price target (down from $5.00) on shares of Aprea Therapeutics in a research report on Thursday, January 29th. Finally, Zacks Research upgraded Aprea Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, February 16th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $5.50.

About Aprea Therapeutics

Aprea Therapeutics is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies that restore tumor suppressor function in cancers driven by TP53 mutations. The company’s lead investigational agent, eprenetapopt (APR-246), is designed to convert mutant p53 protein into a form that induces programmed cell death in malignant cells. Aprea’s research focuses on hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as solid tumors harboring TP53 mutations.

Eprenetapopt has advanced through multiple clinical trials, including pivotal studies assessing its efficacy in combination with hypomethylating agents for patients with MDS.